Publications
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports2012 | First Faculty of Medicine
- Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases - principles and rationale of CZEMP recommendations2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patientsPublication without faculty affiliation
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
Loading network view...